SRTD Biotech
Cell-selective mRNA therapies (seRNA) that switch on only inside diseased cells
Über SRTD Biotech
SRTD Biotech is a Jülich-based biotech company founded in 2019 at Forschungszentrum Jülich. It develops selectively expressed RNA (seRNA): mRNA constructs delivered inactive that switch on only when they detect a disease-specific RNA marker inside a cell, sparing healthy tissue. The platform combines seRNA, proprietary fusogenic lipid nanoparticles for delivery to the liver and other organs, and AI-driven RNA design. Programs target liver and lung cancer, severe liver disease/fibrosis and autoimmune diseases, all preclinical.
Gründer
Bernd Hoffmann
Co-founder & Chief Scientific Officer
Inventor of the seRNA construct and the fusogenic LNP delivery platform. Group leader at Forschungszentrum Jülich, author of 100+ publications and founder of three companies.
Heinz Koeppl
Chief Technology Officer
Professor at TU Darmstadt and director of its Centre for Synthetic Biology; leads target discovery and AI-driven seRNA optimization.
Heribert Bohlen
Co-founder
Jens Hennecke
Chief Business Officer
Leads partnering and corporate development; Managing Director of HBCD Advisors, previously at SOTIO and Micromet.
Matthias Alder
Chief Executive Officer
Appointed CEO after the 2026 seed round. Around 30 years as a biotech executive in the US and Europe, with prior roles at Gain Therapeutics (CEO), Autolus, Cytos, Sucampo, Micromet and Novartis.
- Biotech & Life Sciences
- Jülich, Deutschland
- Seed
- 2019
Finanzierungsrunden
| Datum | Runde | Betrag | Lead-Investoren |
|---|---|---|---|
| Seed | 31,5 Mio. € | Mérieux Equity Partners (lead); NRW.BANK and Boehringer Ingelheim Venture Fund (co-leads) | |
| Seed | Nicht bekannt | High-Tech Gründerfonds (HTGF) |
